#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=FIGS. 6(A) and 6(B) show graphically results of competitive binding assays of antibody-maytansinoid conjugates.
1-1	0-4	FIGS	_	_	
1-2	4-5	.	_	_	
1-3	6-7	6	_	_	
1-4	7-8	(	_	_	
1-5	8-9	A	_	_	
1-6	9-10	)	_	_	
1-7	11-14	and	_	_	
1-8	15-16	6	_	_	
1-9	16-17	(	_	_	
1-10	17-18	B	_	_	
1-11	18-19	)	_	_	
1-12	20-24	show	_	_	
1-13	25-36	graphically	_	_	
1-14	37-44	results	_	_	
1-15	45-47	of	_	_	
1-16	48-59	competitive	_	_	
1-17	60-67	binding	_	_	
1-18	68-74	assays	_	_	
1-19	75-77	of	_	_	
1-20	78-99	antibody-maytansinoid	_	_	
1-21	100-110	conjugates	_	_	
1-22	110-111	.	_	_	

#Text=FIG. 7 shows graphically the blood clearance of an antibody-maytansinoid conjugate in mice.
2-1	112-115	FIG	_	_	
2-2	115-116	.	_	_	
2-3	117-118	7	_	_	
2-4	119-124	shows	_	_	
2-5	125-136	graphically	_	_	
2-6	137-140	the	_	_	
2-7	141-146	blood	_	_	
2-8	147-156	clearance	_	_	
2-9	157-159	of	_	_	
2-10	160-162	an	_	_	
2-11	163-184	antibody-maytansinoid	_	_	
2-12	185-194	conjugate	_	_	
2-13	195-197	in	_	_	
2-14	198-202	mice	_	_	
2-15	202-203	.	_	_	

#Text=This invention is based on the synthesis of novel maytansinoid derivatives that retain high cytotoxicity and that can be effectively linked to cell binding agents.
3-1	204-208	This	_	_	
3-2	209-218	invention	_	_	
3-3	219-221	is	_	_	
3-4	222-227	based	_	_	
3-5	228-230	on	_	_	
3-6	231-234	the	_	_	
3-7	235-244	synthesis	_	_	
3-8	245-247	of	_	_	
3-9	248-253	novel	_	_	
3-10	254-266	maytansinoid	_	_	
3-11	267-278	derivatives	_	_	
3-12	279-283	that	_	_	
3-13	284-290	retain	_	_	
3-14	291-295	high	_	_	
3-15	296-308	cytotoxicity	_	_	
3-16	309-312	and	_	_	
3-17	313-317	that	_	_	
3-18	318-321	can	_	_	
3-19	322-324	be	_	_	
3-20	325-336	effectively	_	_	
3-21	337-343	linked	_	_	
3-22	344-346	to	_	_	
3-23	347-351	cell	_	_	
3-24	352-359	binding	_	_	
3-25	360-366	agents	_	_	
3-26	366-367	.	_	_	

#Text=The art reveals that it is extremely difficult to modify existing drugs without diminishing their cytotoxic potential.
4-1	368-371	The	*[1]	5-5[2_1]	
4-2	372-375	art	*[1]	_	
4-3	376-383	reveals	*[1]	_	
4-4	384-388	that	*[1]	_	
4-5	389-391	it	*[1]	_	
4-6	392-394	is	*[1]	_	
4-7	395-404	extremely	*[1]	_	
4-8	405-414	difficult	*[1]	_	
4-9	415-417	to	*[1]	_	
4-10	418-424	modify	*[1]	_	
4-11	425-433	existing	*[1]	_	
4-12	434-439	drugs	*[1]	_	
4-13	440-447	without	*[1]	_	
4-14	448-459	diminishing	*[1]	_	
4-15	460-465	their	*[1]	_	
4-16	466-475	cytotoxic	*[1]	_	
4-17	476-485	potential	*[1]	_	
4-18	485-486	.	*[1]	_	

#Text=The disclosed invention overcomes this problem by modifying the disclosed maytansinoid derivatives with chemical moieties, especially ones containing thiol or disulfide groups, to which appropriate cell binding agents can be linked.
5-1	487-490	The	_	_	
5-2	491-500	disclosed	_	_	
5-3	501-510	invention	_	_	
5-4	511-520	overcomes	_	_	
5-5	521-525	this	*[2]	_	
5-6	526-533	problem	*[2]	_	
5-7	534-536	by	_	_	
5-8	537-546	modifying	_	_	
5-9	547-550	the	_	_	
5-10	551-560	disclosed	_	_	
5-11	561-573	maytansinoid	_	_	
5-12	574-585	derivatives	_	_	
5-13	586-590	with	_	_	
5-14	591-599	chemical	_	_	
5-15	600-608	moieties	_	_	
5-16	608-609	,	_	_	
5-17	610-620	especially	_	_	
5-18	621-625	ones	_	_	
5-19	626-636	containing	_	_	
5-20	637-642	thiol	_	_	
5-21	643-645	or	_	_	
5-22	646-655	disulfide	_	_	
5-23	656-662	groups	_	_	
5-24	662-663	,	_	_	
5-25	664-666	to	_	_	
5-26	667-672	which	_	_	
5-27	673-684	appropriate	_	_	
5-28	685-689	cell	_	_	
5-29	690-697	binding	_	_	
5-30	698-704	agents	_	_	
5-31	705-708	can	_	_	
5-32	709-711	be	_	_	
5-33	712-718	linked	_	_	
5-34	718-719	.	_	_	

#Text=As a result, the disclosed novel maytansinoid derivatives preserve and in some cases even enhance the cytotoxic potency of the naturally occurring maytansinoids.
6-1	720-722	As	_	_	
6-2	723-724	a	_	_	
6-3	725-731	result	_	_	
6-4	731-732	,	_	_	
6-5	733-736	the	_	_	
6-6	737-746	disclosed	_	_	
6-7	747-752	novel	_	_	
6-8	753-765	maytansinoid	_	_	
6-9	766-777	derivatives	_	_	
6-10	778-786	preserve	_	_	
6-11	787-790	and	_	_	
6-12	791-793	in	_	_	
6-13	794-798	some	_	_	
6-14	799-804	cases	_	_	
6-15	805-809	even	_	_	
6-16	810-817	enhance	_	_	
6-17	818-821	the	_	_	
6-18	822-831	cytotoxic	_	_	
6-19	832-839	potency	_	_	
6-20	840-842	of	_	_	
6-21	843-846	the	_	_	
6-22	847-856	naturally	_	_	
6-23	857-866	occurring	_	_	
6-24	867-880	maytansinoids	_	_	
6-25	880-881	.	_	_	

#Text=The cell binding agent-maytansinoid derivative conjugates permit the full measure of the cytotoxic action of the maytansinoid derivatives to be applied in a targeted fashion against unwanted cells only, therefore, avoiding side effects due to damage to non-targeted healthy cells.
7-1	882-885	The	_	_	
7-2	886-890	cell	_	_	
7-3	891-898	binding	_	_	
7-4	899-917	agent-maytansinoid	_	_	
7-5	918-928	derivative	_	_	
7-6	929-939	conjugates	_	_	
7-7	940-946	permit	_	_	
7-8	947-950	the	_	_	
7-9	951-955	full	_	_	
7-10	956-963	measure	_	_	
7-11	964-966	of	_	_	
7-12	967-970	the	_	_	
7-13	971-980	cytotoxic	_	_	
7-14	981-987	action	_	_	
7-15	988-990	of	_	_	
7-16	991-994	the	_	_	
7-17	995-1007	maytansinoid	_	_	
7-18	1008-1019	derivatives	_	_	
7-19	1020-1022	to	_	_	
7-20	1023-1025	be	_	_	
7-21	1026-1033	applied	_	_	
7-22	1034-1036	in	_	_	
7-23	1037-1038	a	_	_	
7-24	1039-1047	targeted	_	_	
7-25	1048-1055	fashion	_	_	
7-26	1056-1063	against	_	_	
7-27	1064-1072	unwanted	_	_	
7-28	1073-1078	cells	_	_	
7-29	1079-1083	only	_	_	
7-30	1083-1084	,	_	_	
7-31	1085-1094	therefore	_	_	
7-32	1094-1095	,	_	_	
7-33	1096-1104	avoiding	_	_	
7-34	1105-1109	side	_	_	
7-35	1110-1117	effects	_	_	
7-36	1118-1121	due	_	_	
7-37	1122-1124	to	_	_	
7-38	1125-1131	damage	_	_	
7-39	1132-1134	to	_	_	
7-40	1135-1147	non-targeted	_	_	
7-41	1148-1155	healthy	_	_	
7-42	1156-1161	cells	_	_	
7-43	1161-1162	.	_	_	

#Text=This invention permits the maytansinoid derivatives to live up to their potential, something their undirected cytotoxic effects had previously made impossible.
8-1	1163-1167	This	_	_	
8-2	1168-1177	invention	_	_	
8-3	1178-1185	permits	_	_	
8-4	1186-1189	the	_	_	
8-5	1190-1202	maytansinoid	_	_	
8-6	1203-1214	derivatives	_	_	
8-7	1215-1217	to	_	_	
8-8	1218-1222	live	_	_	
8-9	1223-1225	up	_	_	
8-10	1226-1228	to	_	_	
8-11	1229-1234	their	_	_	
8-12	1235-1244	potential	_	_	
8-13	1244-1245	,	_	_	
8-14	1246-1255	something	_	_	
8-15	1256-1261	their	_	_	
8-16	1262-1272	undirected	_	_	
8-17	1273-1282	cytotoxic	_	_	
8-18	1283-1290	effects	_	_	
8-19	1291-1294	had	_	_	
8-20	1295-1305	previously	_	_	
8-21	1306-1310	made	_	_	
8-22	1311-1321	impossible	_	_	
8-23	1321-1322	.	_	_	

#Text=Thus the invention provides useful agents for the elimination of diseased or abnormal cells that are to be killed or lysed such as tumor cells (particularly solid tumor cells), virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells (cells that produce autoantibodies), activated cells (those involved in graft rejection or graft vs. host disease), or any other type of diseased or abnormal cells, while exhibiting a minimum of side effects.
9-1	1323-1327	Thus	_	_	
9-2	1328-1331	the	_	_	
9-3	1332-1341	invention	_	_	
9-4	1342-1350	provides	_	_	
9-5	1351-1357	useful	_	_	
9-6	1358-1364	agents	_	_	
9-7	1365-1368	for	_	_	
9-8	1369-1372	the	_	_	
9-9	1373-1384	elimination	_	_	
9-10	1385-1387	of	_	_	
9-11	1388-1396	diseased	_	_	
9-12	1397-1399	or	_	_	
9-13	1400-1408	abnormal	_	_	
9-14	1409-1414	cells	_	_	
9-15	1415-1419	that	_	_	
9-16	1420-1423	are	_	_	
9-17	1424-1426	to	_	_	
9-18	1427-1429	be	_	_	
9-19	1430-1436	killed	_	_	
9-20	1437-1439	or	_	_	
9-21	1440-1445	lysed	_	_	
9-22	1446-1450	such	_	_	
9-23	1451-1453	as	_	_	
9-24	1454-1459	tumor	_	_	
9-25	1460-1465	cells	_	_	
9-26	1466-1467	(	_	_	
9-27	1467-1479	particularly	_	_	
9-28	1480-1485	solid	_	_	
9-29	1486-1491	tumor	_	_	
9-30	1492-1497	cells	_	_	
9-31	1497-1498	)	_	_	
9-32	1498-1499	,	_	_	
9-33	1500-1505	virus	_	_	
9-34	1506-1514	infected	_	_	
9-35	1515-1520	cells	_	_	
9-36	1520-1521	,	_	_	
9-37	1522-1535	microorganism	_	_	
9-38	1536-1544	infected	_	_	
9-39	1545-1550	cells	_	_	
9-40	1550-1551	,	_	_	
9-41	1552-1560	parasite	_	_	
9-42	1561-1569	infected	_	_	
9-43	1570-1575	cells	_	_	
9-44	1575-1576	,	_	_	
9-45	1577-1587	autoimmune	_	_	
9-46	1588-1593	cells	_	_	
9-47	1594-1595	(	_	_	
9-48	1595-1600	cells	_	_	
9-49	1601-1605	that	_	_	
9-50	1606-1613	produce	_	_	
9-51	1614-1628	autoantibodies	_	_	
9-52	1628-1629	)	_	_	
9-53	1629-1630	,	_	_	
9-54	1631-1640	activated	_	_	
9-55	1641-1646	cells	_	_	
9-56	1647-1648	(	_	_	
9-57	1648-1653	those	_	_	
9-58	1654-1662	involved	_	_	
9-59	1663-1665	in	_	_	
9-60	1666-1671	graft	_	_	
9-61	1672-1681	rejection	_	_	
9-62	1682-1684	or	_	_	
9-63	1685-1690	graft	_	_	
9-64	1691-1693	vs	_	_	
9-65	1693-1694	.	_	_	
9-66	1695-1699	host	_	_	
9-67	1700-1707	disease	_	_	
9-68	1707-1708	)	_	_	
9-69	1708-1709	,	_	_	
9-70	1710-1712	or	_	_	
9-71	1713-1716	any	_	_	
9-72	1717-1722	other	_	_	
9-73	1723-1727	type	_	_	
9-74	1728-1730	of	_	_	
9-75	1731-1739	diseased	_	_	
9-76	1740-1742	or	_	_	
9-77	1743-1751	abnormal	_	_	
9-78	1752-1757	cells	_	_	
9-79	1757-1758	,	_	_	
9-80	1759-1764	while	_	_	
9-81	1765-1775	exhibiting	_	_	
9-82	1776-1777	a	_	_	
9-83	1778-1785	minimum	_	_	
9-84	1786-1788	of	_	_	
9-85	1789-1793	side	_	_	
9-86	1794-1801	effects	_	_	
9-87	1801-1802	.	_	_	

#Text=Thus, this invention teaches the synthesis of maytansinoid derivatives that can be chemically linked to a cell binding agent while keeping a high cytotoxicity either in bound form or in released form or in both states.
10-1	1803-1807	Thus	_	_	
10-2	1807-1808	,	_	_	
10-3	1809-1813	this	_	_	
10-4	1814-1823	invention	_	_	
10-5	1824-1831	teaches	_	_	
10-6	1832-1835	the	_	_	
10-7	1836-1845	synthesis	_	_	
10-8	1846-1848	of	_	_	
10-9	1849-1861	maytansinoid	_	_	
10-10	1862-1873	derivatives	_	_	
10-11	1874-1878	that	_	_	
10-12	1879-1882	can	_	_	
10-13	1883-1885	be	_	_	
10-14	1886-1896	chemically	_	_	
10-15	1897-1903	linked	_	_	
10-16	1904-1906	to	_	_	
10-17	1907-1908	a	_	_	
10-18	1909-1913	cell	_	_	
10-19	1914-1921	binding	_	_	
10-20	1922-1927	agent	_	_	
10-21	1928-1933	while	_	_	
10-22	1934-1941	keeping	_	_	
10-23	1942-1943	a	_	_	
10-24	1944-1948	high	_	_	
10-25	1949-1961	cytotoxicity	_	_	
10-26	1962-1968	either	_	_	
10-27	1969-1971	in	_	_	
10-28	1972-1977	bound	_	_	
10-29	1978-1982	form	_	_	
10-30	1983-1985	or	_	_	
10-31	1986-1988	in	_	_	
10-32	1989-1997	released	_	_	
10-33	1998-2002	form	_	_	
10-34	2003-2005	or	_	_	
10-35	2006-2008	in	_	_	
10-36	2009-2013	both	_	_	
10-37	2014-2020	states	_	_	
10-38	2020-2021	.	_	_	

#Text=High cytotoxicity is defined as exhibiting a toxicity having an IC.sub.50 --the inhibiting concentration of a toxic substance that leaves a surviving fraction of 0.5--of about 10.sup.-8 M or less when measured in vitro with KB cells upon a 24 hour exposure time to the drug.
11-1	2022-2026	High	_	_	
11-2	2027-2039	cytotoxicity	_	_	
11-3	2040-2042	is	_	_	
11-4	2043-2050	defined	_	_	
11-5	2051-2053	as	_	_	
11-6	2054-2064	exhibiting	_	_	
11-7	2065-2066	a	_	_	
11-8	2067-2075	toxicity	_	_	
11-9	2076-2082	having	_	_	
11-10	2083-2085	an	_	_	
11-11	2086-2092	IC.sub	_	_	
11-12	2092-2095	.50	_	_	
11-13	2096-2097	-	_	_	
11-14	2097-2098	-	_	_	
11-15	2098-2101	the	_	_	
11-16	2102-2112	inhibiting	_	_	
11-17	2113-2126	concentration	_	_	
11-18	2127-2129	of	_	_	
11-19	2130-2131	a	_	_	
11-20	2132-2137	toxic	_	_	
11-21	2138-2147	substance	_	_	
11-22	2148-2152	that	_	_	
11-23	2153-2159	leaves	_	_	
11-24	2160-2161	a	_	_	
11-25	2162-2171	surviving	_	_	
11-26	2172-2180	fraction	_	_	
11-27	2181-2183	of	_	_	
11-28	2184-2187	0.5	_	_	
11-29	2187-2188	-	_	_	
11-30	2188-2189	-	_	_	
11-31	2189-2191	of	_	_	
11-32	2192-2197	about	_	_	
11-33	2198-2200	10	_	_	
11-34	2200-2201	.	_	_	
11-35	2201-2204	sup	_	_	
11-36	2204-2205	.	_	_	
11-37	2205-2206	-	_	_	
11-38	2206-2207	8	_	_	
11-39	2208-2209	M	_	_	
11-40	2210-2212	or	_	_	
11-41	2213-2217	less	_	_	
11-42	2218-2222	when	_	_	
11-43	2223-2231	measured	_	_	
11-44	2232-2234	in	_	_	
11-45	2235-2240	vitro	_	_	
11-46	2241-2245	with	_	_	
11-47	2246-2248	KB	_	_	
11-48	2249-2254	cells	_	_	
11-49	2255-2259	upon	_	_	
11-50	2260-2261	a	_	_	
11-51	2262-2264	24	_	_	
11-52	2265-2269	hour	_	_	
11-53	2270-2278	exposure	_	_	
11-54	2279-2283	time	_	_	
11-55	2284-2286	to	_	_	
11-56	2287-2290	the	_	_	
11-57	2291-2295	drug	_	_	
11-58	2295-2296	.	_	_	

#Text=Cytotoxic Agent
12-1	2297-2306	Cytotoxic	_	_	
12-2	2307-2312	Agent	_	_	
